Abstracts Archive - Page 723 of 2425 - ACR Meeting Abstracts

Abstract Number: 1437 • ACR Convergence 2020
Measuring Disease Activity and Functional Status in Patients with Granulomatosis with Polyangiitis (Wegener’s) (GPA)
Kinanah Yaseen¹, Isaac Briskin¹ and Rula Hajj-ali², ¹Cleveland Clinic Foundation, Cleveland, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: Variable association between vasculitis activity and patient reported outcomes was reported in small groups of Granulomatosis with polyangiitis (GPA) patients in the literature so…
Abstract Number: 1436 • ACR Convergence 2020
Incidence Rate, Predictors and Outcome of Stroke in Patients with ANCA Associated Vasculitis – A Population-based Study
Dennis Tabakovic¹, Rona Smith², David Jayne³ and Aladdin Mohammad⁴, ¹Lund University, Lund, Skane Lan, Sweden, ²University of Cambridge, Cambridge, United Kingdom, ³Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, ⁴Lund University, Lund, Sweden. Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Lund, Sweden
Background/Purpose: To study the incidence rate, predictors and outcome of stroke in patients with ANCA-associated vasculitis (AAV) within a defined population in southern Sweden.Methods: The…
Abstract Number: 1442 • ACR Convergence 2020
Denosumab versus Oral Bisphosphonate for Osteoporosis in Long-term Glucocorticoid Users: A 12-month Randomized Controlled Trial
Chi Chiu Mok¹, Ling Yin Ho¹ and Kwok Man Ma¹, ¹Tuen Mun Hospital, Hong Kong, China (People's Republic)
Background/Purpose: To compare the efficacy of denosumab (DEN) and oral alendronate (ALN) on spinal bone mineral density (BMD) in long-term glucocorticoid users.Methods: Patients receiving long-term…
Abstract Number: 1444 • ACR Convergence 2020
Cluster-randomized Pragmatic Clinical Trial Evaluating the Potential Benefit of a Tight-control and Treat-to-target Strategy in Axial Spondyloarthritis: The Results of the TICOSPA Trial
Anna Molto¹, Clementina Lopez-Medina², Filip Van den Bosch³, Annelies Boonen⁴, Casper Webers⁴, Emmanuelle Dernis⁵, Floris van Gaalen⁶, Martin Soubrier⁷, Pascal Claudepierre⁸, Athan Baillet⁹, Mirian Starsman-Kool¹⁰, Anneke Spoorenberg¹¹, Désirée van der Heijde¹² and Maxime Dougados¹³, ¹Rheumatology Department, Cochin Hospital, APHP, Paris, France, Paris, France, ²INSERM U1153, Universtity of Paris, PAris, France, ³Ghent University Hospital, Ghent, Belgium, ⁴Maastricht University Medical Center, Maastricht, Netherlands, ⁵CH Le Mans, department of rheumatology, Le Mans, France, ⁶Leiden University Medical Center (LUMC), Leiden, Netherlands, ⁷CHU Gabriel Montpied, Clermont-Ferrand, France, ⁸Hôpital Henri Mondor, Université Paris Est Créteil, EA 7379 EpiDermE, department of rheumatology, Créteil, France, ⁹CHU Grenoble, Echirolles, France, ¹⁰ATRIUM Medical Center, Heerlen, ¹¹University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands, ¹²Leiden University Medical Center, Leiden, Netherlands, ¹³Université de Paris, Department of Rheumatology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France
Background/Purpose: Recommendations for axial spondyloarthritis (axSpA) management include tight control and treat-to-target (TC), but no study has evaluated its potential benefit. The objective of this…
Abstract Number: 1439 • ACR Convergence 2020
Proteinase 3-Reactive B Cell Pool Restructuring After Rituximab and Risk of Relapse in Severe PR3-ANCA-Associated Vasculitis
Alvise Berti¹, Sophie Hillion², Marta Casal Moura¹, Amber Hummel¹, Eva Carmona¹, Tobias Peikert¹, Carol Langford³, Peter A. Merkel⁴, Paul Monach⁵, Philip Seo⁶, Robert Spiera⁷, Eugene St Clair⁸, Fernando C. Fervenza¹, Kristina Harris⁹, John H. Stone¹⁰, Jacques-Olivier Pers¹¹, Ulrich Specks¹ and Divi Cornec¹², ¹Mayo Clinic, Rochester, MN, ²Brest University, Brest, Bretagne, France, ³Cleveland Clinic, Moreland Hills, OH, ⁴Division of Rheumatology University of Pennsylvania, Philadelphia, PA, ⁵Brigham and Women's, Boston, ⁶Johns Hopkins University, Baltimore, MD, ⁷Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA, New York, NY, ⁸Duke University, Durham, NC, ⁹Immune Tolerance Network, Bethesda, MD, ¹⁰Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹¹University of Brest, Brest, France, ¹²Rheumatology Department, Brest University Hospital, Brest, France
Background/Purpose: In ANCA-associated vasculitis (AAV) B cells play a central pathogenic role and are instrumental for the production of ANCA, which are thought to mediate…
Abstract Number: 1434 • ACR Convergence 2020
The Role of Sural Nerve Biopsy in the Diagnosis of Systemic Vasculitis – a Retrospective Study from Two Specialized Centres
Karl Gisslander¹, Lars Dahlin², Rona Smith³, David Jayne³ and Aladdin Mohammad⁴, ¹Lund University, Lund, Sweden, Lund, Sweden, ²Department of Translational Medicine – Hand Surgery, Lund University, Malmö, Sweden, Malmö, Sweden, ³Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, ⁴Lund University, Lund, Sweden. Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Lund, Sweden
Background/Purpose: Vasculitis of the peripheral nervous system is seen mainly in systemic vasculitis involving small and medium sized vessels and in cases of single-organ vasculitis…
Abstract Number: 1447 • ACR Convergence 2020
Vitamin D Deficiency Enhances Antiphospholipid Antibody-Mediated Thrombosis in a Passive Immunization Mouse Model
Rohan Willis¹, Karen Roye-Green², Zurina Romay-Penabad¹, Elizabeth Papalardo¹, Alvaro Schleh³, Vijaya Murthy⁴, Monica Smikle² and Emilio Gonzalez¹, ¹University of Texas Medical Branch, Galveston, TX, ²University of the West Indies, Kingston, Jamaica, ³Antiphospholipid Standardization Laboratory, GALVESTON, TX, ⁴University of Texas Medical Branch, League City, TX
Background/Purpose: Abnormal vitamin D levels occur frequently in antiphospholipid (APS) patients and are correlated with thrombosis. It remains unclear however if vitamin D deficiency observed…
Abstract Number: 1450 • ACR Convergence 2020
Integrative Analysis of DNA Methylation and Gene Expression in Monocytes from Primary Antiphospholipid Syndrome Patients Identifies a Gene Expression Signature Associated with Their Atherothrombotic Phenotype
Carlos Pérez-Sánchez¹, M Angeles Aguirre², Alejandra Maria Patiño-Trives¹, Laura Pérez-Sanchez³, Maria Luque-Tevar¹, Iván Arias de la Rosa¹, María-Carmen Abalos-Aguilera¹, Pedro Segui⁴, Javier Rodriguez-Ubreva⁵, Esteban Ballestar⁵, Nuria Barbarroja¹, Eduardo Collantes-Estévez² and Chary Lopez-Pedrera¹, ¹Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, ³Hospital Universitario Reina Sofía, Córdoba, Spain, ⁴IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, ⁵Josep Carreras Institute (IJC), Badalona, Spain
Background/Purpose: 1. To develop integrated analyses of the genome-wide DNA methylation and gene expression profiles in monocytes from APS patients and assess their involvement in…
Abstract Number: 1451 • ACR Convergence 2020
Longitudinal Assessment of Anti-beta 2 Glycoprotein in SLE
Michelle Petri¹, Laurence Magder² and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: Although anti-beta2 glycoprotein is one of the three antiphospholipid antibodies recognized in the Sydney APS classification criteria, it is one of the least studied. …
Abstract Number: 1446 • ACR Convergence 2020
Pregnancy Outcomes in Patients with Interstitial Lung Disease
Aardra Rajendran¹, Stephanie Giattino², Amanda Eudy³, Aparna Swaminathan⁴ and Megan Clowse⁵, ¹Duke University, Lewisville, NC, ²Duke University, Media, PA, ³Duke University, Durham, NC, ⁴Duke University, Durham, ⁵Duke University, Chapel Hill, NC
Background/Purpose: Patients with interstitial lung disease (ILD) are often recommended to avoid conception or terminate pregnancy despite limited data on pregnancy outcomes and complications. Studies…
Abstract Number: 1457 • ACR Convergence 2020
Two Minute Walking Distance and Other Timed Function Tests Are Superior to MMT-8 in Assessing Outcomes in Polymyositis and Dermatomyositis
Sai kumar Dunga¹, Chengappa G Kavadichanda² and VS Negi², ¹Jawaharlal institute of postgraduate medical education and research, puducherry, India, ²Jawaharlal institute of postgraduate medical education and research, Puducherry, Puducherry, India
Background/Purpose: Inflammatory myositis are heterogenous group of diseases affecting skeletal muscles and multiple different organs. Assessing improvement in disease activity is done by Manual muscle…
Abstract Number: 1454 • ACR Convergence 2020
B Cell-specific TLR7 Regulates Lupus in TLR9 Deficient Mice
Haylee Baxendell¹, Minjung Kim², Jeremy Tilstra² and Mark Shlomchik², ¹University of Pittsburgh, Cranberry Twp, PA, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that results in significant morbidity and mortality. In SLE, endosomal TLR7 and TLR9 are known to…
Abstract Number: 1449 • ACR Convergence 2020
Altered Splicing in Leukocytes from Patients with Antiphospholipid Syndrome, Systemic Lupus Erythematosus and Antiphospholipid Syndrome with Lupus: Clinical Involvement
Alejandra Maria Patiño-Trives¹, Alejandro Ibáñez-Costa², Carlos Pérez-Sánchez¹, Laura Pérez-Sanchez³, Maria Luque-Tevar¹, Iván Arias de la Rosa¹, María-Carmen Abalos-Aguilera¹, Desirée Ruiz-Vilchez⁴, Pedro Segui⁵, Mario Espinosa⁵, Nuria Barbarroja¹, Eduardo Collantes⁴, Justo P. Castaño⁵, Raul M Luque⁵, María de los ángeles Aguirre-Zamorano⁵ and Chary Lopez-Pedrera¹, ¹Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, ³Hospital Universitario Reina Sofía, Córdoba, Spain, ⁴Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁵IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba
Background/Purpose: To identify shared and differential changes in the splicing machinery of immune cells from antiphospholipid syndrome (APS), systemic lupus erythematosus (SLE) and antiphospholipid syndrome…
Abstract Number: 1341 • ACR Convergence 2020
Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis with Inadequate Response to Non-Biologic DMARDs Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Study
Vibeke Strand¹, Philip Mease², Enrique Soriano³, Mitsumasa Kishimoto⁴, Carlo Salvarani⁵, Nemanja Damjanov⁶, Jaclyn K Anderson⁷, Erin Blondell⁷, Patrick Zueger⁷, Christopher Saffore⁷ and Dafna Gladman⁸, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Department of Public Health, Instituto Universitario, Escuela de Medicina Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, Capital Federal, Buenos Aires, Argentina, ⁴Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Yokohama, Japan, ⁵Rheumatology Units, University of Modena and Reggio Emilia, and Azienda USL-IRCCS di Reggio Emilia, REGGIO EMILIA, Italy, ⁶University of Belgrade Medical School, Belgrade, Serbia, ⁷AbbVie Inc., North Chicago, IL, ⁸Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Patient-reported outcomes (PROs) are important when evaluating treatment benefits in PsA. We present an analysis of PRO data from the SELECT-PsA 1 study.Methods: SELECT-PsA…
Abstract Number: 1216 • ACR Convergence 2020
Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, and Health Related Quality of Life, and Reduced Fatigue over Time in Patients with Rheumatoid Arthritis Who Are Methotrexate-Naïve: Results from a Phase 3 Study
Rieke Alten¹, William F. C. Rigby², Alena Pechonkina³, Zhaoyu Yin⁴, Ken Hasegawa⁴, Thijs Hendrikx⁵, Tatsuya Atsumi⁶ and Rene Westhovens⁷, ¹Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Gilead Sciences, Inc., Foster City, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos BV, Leiden, Netherlands, ⁶Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan, ⁷University Hospitals Leuven, Belgium, Leuven, Belgium
Background/Purpose: In FINCH 3, filgotinib (FIL)—a potent, selective, oral JAK1 inhibitor1—in combination with methotrexate (MTX), demonstrated significant improvements in signs and symptoms of rheumatoid arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].